The FDA does not approve compounded medications for safety, quality, or manufacturing
Beyond the traditional M1-M2 paradigm, current transcriptomic analyses reveal greater TAM diversity with seven main subtypes: interferon-primed TAMs (IFN-TAMs), immune regulatory TAMs (Reg-TAMs), inflammatory cytokine-enriched TAMs (Inflam-TAMs), lipid-associated TAMs (LA-TAMs), proangiogenic TAMs (Angio-TAMs), RTM-like TAMs (RTM-TAMs), and proliferating TAMs (Prolif-TAMs) ( Figure 6 ) (94)
The Healthcare Imperative: Lowering Costs and Improving Outcomes: Workshop Series Summary (National Academies Press, 2010)
doi: 10.3390/ijms24086936 324 WirtuSFRamaswamyKMaitraRChopraSMishraAKJuleLT
To achieve remote targeting, it is necessary to ensure that the carrier can be absorbed and transported to the target intact
Figure 2: Changes in the histolopathological scores amongst the four experimental treatment groups